vaginal fluid, saliva, urine, and plasma. Over 8 weeks, plasma was collected weekly and participants self-collected remaining samples daily for one week periods every other week. CMV shedding rates were calculated as number of days with positive results divided by number of days with samples collected. Generalized estimating equations were used to determine associations between shedding at different sites. RESULTS: Nine participants a median of 7 weeks postpartum (range 5-15 weeks) self-collected samples for a median of 28 days (range 26-31 days). CMV was detected in breastmilk in 7 women, vaginal secretions in 3 women, and oral secretions in 2 women. CMV was not detected in urine or plasma samples. CMV was found in most breastmilk samples (171 of 253, 67.6%). CMV shedding in breastmilk persisted up to 17 weeks postpartum. CMV was less frequently detected in the vagina (39 of 258, 15.1%) and saliva (53 of 258, 20.5%). On days with oral CMV shedding, the risk of CMV vaginal detection was increased (RR¼26.1, 95% CI¼3.9 to 176.0). Higher breastmilk CMV quantities were significantly associated with simultaneous oral CMV detection (RR¼4.1, 95% CI 1.9 to 8.8). CONCLUSIONS: Through daily sampling, we found a high frequency and quantity of CMV in breastmilk among CMV-seropositive healthy women up to 17 weeks postpartum. CMV shedding in vaginal fluid and saliva was less frequent; however, vaginal detection was more likely to occur on days when oral CMV shedding was present, and high breastmilk quantities were associated with oral shedding. These data suggest concurrent CMV reactivation at multiple sites in some postpartum women. Our findings may be relevant for the practice of sharing raw breastmilk in the community, particularly for pre-term infants. OBJECTIVES: Sneathia amnii and Sneathia sanguinegens are emerging obstetrical pathogens associated with bacterial vaginosis (BV), preterm labor, post-partum bacteremia, and cervical cancer. Sneathia spp. ascend from the lower genital tract into the uterus and cause infections of the chorioamniotic membranes, amniotic fluid, and fetus. Objectives: Sneathia spp. are difficult to culture, which has resulted in limited knowledge of their virulence mechanisms. The main objective of this study was to identify the core genes present in this genus, as well as the virulence factors and the metabolic pathways differentially present among the two species. METHODS: We performed the first comparative genomics analysis of the Sneathia genus using whole genome sequences, which were recently generated for two strains of S. amnii (T4190-99 and Sn35T) and one strain of S. sanguinegens (CCUG 41628T). Genomes were annotated and analyzed using the RAST, IMG and KEGG pipelines. RESULTS: Although numbers of predicted proteins are very similar for the two species, several genes in carbohydrate and monosaccharide metabolism were found only in S. amnii, suggesting S. sanguinegens, has a more restricted set of fermentation substrates. One pathway found in both species is the arginine dihydrolase pathway, which is used by pathogens (specifically Mycoplasma hominis e another common pathogen causing obstetrical infections) to metabolize host L-arginine and to deplete arginine in the extracellular environment. Depleting arginine allows pathogens to prevent production of bactericidal nitric oxide by host cells and also to interfere with host macrophage operations. Only S. amnii genomes are predicted to metabolize sialic acids, which is implicated in BV pathogenesis as an immune evasion mechanism and also as an important energy source. In contrast, S. sanguinegens alone codes for proteins involved in amino sugar metabolism of hyaluronic acid (HA) and N-acetyl galactosamine. Streptoccoccus agalactiae, another important obstetrical pathogen, was shown in recent literature to use HA metabolism to evade host immunity, ascend the genital tract, and cause fetal demise in a mouse model. CONCLUSIONS: In summary, we have identified differences in the metabolic and virulence potential of Sneathia spp., which may be clinically important. Our future directions include addressing the function of these pathways in cell culture models, as well as in human studies that molecularly resolve Sneathia species and strains.
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25 Comparative genomics identifies genes that may enable sneathia species to ascend into the intrauterine environment T. Jayaprakash, L. K. Sycuro OBJECTIVES: Sneathia amnii and Sneathia sanguinegens are emerging obstetrical pathogens associated with bacterial vaginosis (BV), preterm labor, post-partum bacteremia, and cervical cancer. Sneathia spp. ascend from the lower genital tract into the uterus and cause infections of the chorioamniotic membranes, amniotic fluid, and fetus. Objectives: Sneathia spp. are difficult to culture, which has resulted in limited knowledge of their virulence mechanisms. The main objective of this study was to identify the core genes present in this genus, as well as the virulence factors and the metabolic pathways differentially present among the two species. METHODS: We performed the first comparative genomics analysis of the Sneathia genus using whole genome sequences, which were recently generated for two strains of S. amnii (T4190-99 and Sn35T) and one strain of S. sanguinegens (CCUG 41628T). Genomes were annotated and analyzed using the RAST, IMG and KEGG pipelines. RESULTS: Although numbers of predicted proteins are very similar for the two species, several genes in carbohydrate and monosaccharide metabolism were found only in S. amnii, suggesting S. sanguinegens, has a more restricted set of fermentation substrates. One pathway found in both species is the arginine dihydrolase pathway, which is used by pathogens (specifically Mycoplasma hominis e another common pathogen causing obstetrical infections) to metabolize host L-arginine and to deplete arginine in the extracellular environment. Depleting arginine allows pathogens to prevent production of bactericidal nitric oxide by host cells and also to interfere with host macrophage operations. Only S. amnii genomes are predicted to metabolize sialic acids, which is implicated in BV pathogenesis as an immune evasion mechanism and also as an important energy source. In contrast, S. sanguinegens alone codes for proteins involved in amino sugar metabolism of hyaluronic acid (HA) and N-acetyl galactosamine. Streptoccoccus agalactiae, another important obstetrical pathogen, was shown in recent literature to use HA metabolism to evade host immunity, ascend the genital tract, and cause fetal demise in a mouse model. CONCLUSIONS: In summary, we have identified differences in the metabolic and virulence potential of Sneathia spp., which may be clinically important. Our future directions include addressing the function of these pathways in cell culture models, as well as in human studies that molecularly resolve Sneathia species and strains.
26 Long term outcomes of women with recurrent vulvovaginal candidiasis after a course of maintenance fluconazole OBJECTIVES: For women with recurrent vulvovaginal candidiasis (RVVC), standard therapy includes once or twice weekly fluconazole for 6 months. There is a dearth of data about long-term clinical outcome after such a course. This study sought to determine the rate of long-term recurrence after maintenance therapy. METHODS: A retrospective analysis of women with RVVC due to C. albicans from 1/08 to 12/16 was done. Using chart review and phone calls, information about demographics and recurrence after maintenance was obtained. Patients were defined as resolved if they had no further episodes of VVC, sporadic with <3 episodes of VVC per year, and ongoing with > 3 episodes of VVC per year. RESULTS: 1672 patients with C. albicans vaginal isolates were identified. Of these, 750 were randomly selected and 201 met the criteria for RVVC. The mean age was 40.4; 77.4% were white. 17.2% were menopausal with 78.7% of them on estrogen. 67.2% had comorbid vulvar conditions. 31.8% had any of the following risk factors for RVVC: antibiotic use, estrogen use and diabetes. The mean length of maintenance therapy was 9.4 months. 120 complete charts were further analyzed. The mean length of follow-up after discontinuing maintenance therapy was 39.9 months. After the initial course, 19.2%, 17.5%, and 63.3% were resolved, sporadic and ongoing, respectively. Risk factors, comorbid vulvar conditions, obesity, menopause status and length of therapy were not associated with relapse. For those receiving a second course of maintenance, the mean time to relapse was 20.9 months. 11.4% reported possible adverse effects with fluconazole, including 4% with gastrointestinal symptoms, 2.5% with hair loss, 1% with elevated liver enzymes, and 0.5% with rash. CONCLUSIONS: Although RVVC can be controlled, relapse is common after an initial course of maintenance fluconazole. Ongoing maintenance remains the most effective treatment option. 
OBJECTIVES:
To evaluate the antimicrobial activity of a Chinese medicine, the Baofukang suppository as a potential antifungal drug for the prevention of Vulvovaginal Candidiasis (VVC).
METHODS:
We evaluated the cytotoxic activity of the Baofukang suppository using the VK2/E6E7 vaginal epithelial cell (VEC) line. An ELISA analysis was made to evaluate three kinds of cytokines (Th1, Th2 and Th17 types) and non-B IgG in the supernatants. SEM was conducted to observe ultrastructural changes of VECs. RESULTS: When treated with the Baofukang suppository, all of the immunocompetent cytokines and chemokines (e.g., IL-2, IL-4, IL-6, IL-8, and IL-17) by infected VK2/E6E7 cells was statistically upregulated (P < 0.05), except IL-4 (11.70 AE 1.82 vs. 14.88 AE 4.72, P ¼ 0.343) compared to the infected control cells. The secretion of non-B IgG also exhibited the same trend. Our scanning electron microscopy results revealed that C. albicans can invade VECs by both induced endocytosis and active penetration. The Baofukang suppository could effectively inhibit the adhesion, hyphal formation, and proliferation, as well as notably restore the vaginal epithelial cell morphology, viability, and enhance the local immune function of the VECs. CONCLUSIONS: These preliminary results suggest promising antimicrobial properties of the Baofukang suppository, which may be efficacious as an antifungal therapy candidate via up-regulating Th1 cellular immunity, the Th17-axis of the innate immune response, and the secretion of vaginal epithelial-derived IgG. These combined effects collectively restore the immune function of the infected VECs against C. albicans in vitro. 
Ovariectomized female Wistar rats (N¼6/group) were used. Estradiol (5 mg/kg) was administered SC on days -7, -5, -3, -1, 1, 3, 5 and 7 relative to day of infection (day 0). Rats were infected by intravaginal administration (0.1 mL) under isoflurane anaesthesia with C. albicans 529L (9.8x10 ˇ 4 CFU/rat). Treatments started at 24 h post infection: CD101 (5 or 10 mg/kg SC) once daily for 1 or 2 days; fluconazole (PO 20 mg/kg) once daily for 1 or 2 days; vehicle (SC) once daily for 2 days. C. albicans CFU was determined by quantitative culture of vaginal lavage samples. Lavage samples were obtained on days 1 (pre-treatment), 2, 3, 5, 7 and 9 days post infection by flushing rat vaginas 4 times with 0.1 mL of PBS. Rats were euthanized on day 9 for CFU enumeration of vaginal tissue (including uterine horns). RESULTS: A robust VVC model was established; vehicle-treated rats maintained a high fungal burden throughout the study, rising to 2x10 ˇ 4 CFU/mL by day 9 post infection. CD101 administered once at 10 mg/kg was the most effective dose and similar to fluconazole dosed at 20 mg/kg showing comparable CFU by day 5 post infection. As expected, day 9 tissue CFU were higher than lavage CFU for all treatments, but the overall pattern was similar to lavage CFU. All but 1 rat treated with CD101 once at 10 mg/kg had undetectable CFU. CONCLUSIONS: In conclusion, CD101 given as a single dose of CD101 10 mg/kg (equivalent to 200 mg in human) substantially reduced vaginal lavage and tissue CFU, with clearance to below-detectable levels in 5 of 6 rats. These results suggest excellent CD101 distribution/penetration into vaginal mucosa via a single SC dose and warrant further investigation. OBJECTIVES: Gonorrhea, caused by Neisseria gonorrhoeae (GC), is one of the most common sexually transmitted infections and has emerged as a public health crisis due to increases in the multidrug resistance of the bacteria. However, the pathogenesis of this disease is not well understood due to a lack of infection models that mimic the disease in vivo. GC primarily infect the human genital tract. Multiple surface molecules of this bacterium, including opacity-associated protein (Opa), undergo phase variation. Female infections can lead to various clinical outcomes, ranging from no symptom to severe complications including pelvic inflammatory disease, infertility, and life-threatening ectopic pregnancy. GC infection in the female reproductive tract starts from the cervix, which is protected by various types of epithelial cell barriers: non-polarized multilayer squamous at the ectocervix, polarized monolayer columnar at the endocervix, and transforming epithelial cells in between. The objective of this study is to understand the cellular and molecular mechanisms by which GC overcome the mucosal epithelial barrier of the female reproductive tract to establish infection. METHODS: We developed an ex vivo infection model using human cervical tissues and in vitro infection models with three-dimensional epithelial cell cultures, as well as bacterial strains expressing no Opa or defined Opa proteins. We analyzed GC colonization at and penetration into the epithelium as well as GC-induced epithelial exfoliation and cell-cell junction disruption by gentamicin-resistance assay and immunofluorescence microscopy. RESULTS: Our results show that GC can penetrate into the subepithelium of the endocervix and the transformational zone but not that of the endocervix, even though GC colonize the mucosal surface and induce the epithelial exfoliation at all three regions of the cervix equally. When an isoform of Opa that binds to the host receptor CEACAM is expressed on GC, it enhances GC colonization while inhibiting GC penetration into the endocervical epithelium. However, in the transformational zone where epithelial cells do not express CEACAM on their surface, GC colonization and penetration are independent of Opa expression. GC break the cervical epithelial barrier by disrupting epithelial cell-cell interactions mediated by E-cadherin, which leads to GC penetration. The expression of CEACAM-binding Opa inhibits GC-induced disruption of the epithelial cell-cell interaction. CONCLUSIONS: This study demonstrates that GC modify their infection mechanism based on the type of epithelial cells with which they interact and break the epithelial barrier by hijacking the internal mechanisms of epithelial cells. Phase variation of the GC surface molecule Opa regulates the magnitude of the damage in the epithelial barrier, consequently changing clinical outcomes of the infection.
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